Loss of ATP13A2 impairs glycolytic function in Kufor-Rakeb syndrome patient-derived cell models
- 1 June 2016
- journal article
- research article
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 27, 67-73
Abstract
No abstract availableKeywords
Funding Information
- NSW
- NHMRC early career fellow (APP1037797)
- NHMRC (APP1008433)
- Australian Mitochondrial Disease Foundation
This publication has 29 references indexed in Scilit:
- The role of ATP13A2 in Parkinson's disease: Clinical phenotypes and molecular mechanismsMovement Disorders, 2015
- Parkinson's disease-linked human PARK9/ATP13A2 maintains zinc homeostasis and promotes α-Synuclein externalization via exosomesHuman Molecular Genetics, 2014
- Parkinson's disease-associated human ATP13A2 (PARK9) deficiency causes zinc dyshomeostasis and mitochondrial dysfunctionHuman Molecular Genetics, 2014
- Zn2+ dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulationHuman Molecular Genetics, 2013
- Patterns of levels of biological metals in CSF differ among neurodegenerative diseasesJournal of the Neurological Sciences, 2011
- Clinical spectrum of Kufor‐Rakeb syndrome in the Chilean kindred with ATP13A2 mutationsMovement Disorders, 2010
- Zinc in the physiology and pathology of the CNSNature Reviews Neuroscience, 2009
- Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPaseNature Genetics, 2006
- Zinc causes loss of membrane potential and elevates reactive oxygen species in rat brain mitochondriaMitochondrion, 2005
- ALTERATIONS IN THE LEVELS OF IRON, FERRITIN AND OTHER TRACE METALS IN PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES AFFECTING THE BASAL GANGLIABrain, 1991